CD22 and acute lymphoblastic leukemia: Due to the expression of CD22 not only on healthy but also malignant B-cells, CD22 is currently assessed as a target for CAR- and mAb-based immunotherapy approaches in the treatment of mainly ALL and B-cell lymphoma [16–19].